|
Arias-Martinez A, Martinez de Castro E, Gallego J, Arrazubi V, Custodio A, Fernandez Montes A, Diez M, Hernandez R, Limon ML, Cano JM, Vidal-Tocino R, Macias I, Visa L, Martin Richard M, Sauri T, Hierro C, Gil M, Cerda P, Martinez Moreno E, Martinez Lago N, Merida-Garcia AJ, Gomez Gonzalez L, Garcia Navalon FJ, Ruiz Martin M, Marin G, Lopez-Lopez F, Ruperez Blanco AB, Fernandez AF, Jimenez-Fonseca P, Carmona-Bayonas A, Alvarez-Mancenido F. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry. Clin Transl Oncol. 2024 Jul;26(7):1674-1686. doi: 10.1007/s12094-024-03388-6. Epub 2024 Feb 15. PubMed PMID: 38361134; PubMed Central PMCID: PMC11178610.
AÑO: 2024; IF: 2.5
|
38361134
|
Mihic-Gongora L, Jimenez-Fonseca P, Coca-Membribes S, Cruz-Castellanos P, Galan-Moral R, Asensio-Martinez E, Palacin-Lois M, Carmona-Bayonas A, Carames-Sanchez C, Calderon C. Physical Activity in Patients with Advanced Cancer: Sociodemographic, Clinical, and Psychological Correlates. Brain Sci. 2024 Jun 3;14(6):573. doi: 10.3390/brainsci14060573. PubMed PMID: 38928572; PubMed Central PMCID: PMC11201712.
AÑO: 2024; IF: 2.8
|
|
Velasco-Durantez V, Cruz-Castellanos P, Hernandez R, Rodriguez-Gonzalez A, Fernandez Montes A, Gallego A, Manzano-Fernandez A, Sorribes E, Zafra M, Carmona-Bayonas A, Calderon C, Jimenez-Fonseca P. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients. Sci Rep. 2024 Feb 7;14(1):3188. doi: 10.1038/s41598-024-53212-y. PubMed PMID: 38326426; PubMed Central PMCID: PMC10850144.
AÑO: 2024; IF: 3.9
|
|
Pacheco-Barcia V, Custodio-Cabello S, Carrasco-Valero F, Palka-Kotlowska M, Marino-Mendez A, Carmona-Bayonas A, Gallego J, Martin AJM, Jimenez-Fonseca P, Cabezon-Gutierrez L. Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial. World J Gastrointest Oncol. 2024 Feb 15;16(2):386-397. doi: 10.4251/wjgo.v16.i2.386. PubMed PMID: 38425396; PubMed Central PMCID: PMC10900150.
AÑO: 2024; IF: 2.5
|
|
Jimenez-Fonseca P, Foy V, Raby S, Carmona-Bayonas A, Macia-Rivas L, Arrazubi V, Cacho Lavin D, Hernandez San Gil R, Custodio A, Cano JM, Fernandez Montes A, Mirallas O, Macias Declara I, Vidal Tocino R, Visa L, Limon ML, Pimentel P, Martinez Lago N, Sauri T, Martin Richard M, Mangas M, Gil Raga M, Calvo A, Reguera P, Granja M, Martin Carnicero A, Hernandez Perez C, Cerda P, Gomez Gonzalez L, Garcia Navalon F, Pacheco Barcia V, Gutierrez Abad D, Ruiz Martin M, Weaver J, Mansoor W, Gallego J. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157641. doi: 10.1177/17588359231157641. eCollection 2023. PubMed PMID: 36895850; PubMed Central PMCID: PMC9989382.
AÑO: 2023; IF: 4.3
|